137 related articles for article (PubMed ID: 37037194)
1. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
[TBL] [Abstract][Full Text] [Related]
2. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
3. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
[TBL] [Abstract][Full Text] [Related]
4. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Kim D; Goh HG; Kim SH; Cho BS; Kim DW
Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
[TBL] [Abstract][Full Text] [Related]
5. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
6. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia.
Alqattan Y; Ali S; Almohammad R; Kayali N; Alhuraiji A
Gulf J Oncolog; 2022 Sep; 1(40):74-77. PubMed ID: 36448074
[TBL] [Abstract][Full Text] [Related]
10. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
12. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
14. [Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Yang L; Lu N; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1348-1353. PubMed ID: 27784355
[TBL] [Abstract][Full Text] [Related]
15. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
16. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
[TBL] [Abstract][Full Text] [Related]
17. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Aslan NA; Hıncal HO; Elver Ö; Erol V; Güler N
J Oncol Pharm Pract; 2023 Mar; 29(2):511-516. PubMed ID: 35821583
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
20. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]